Bristol-Myers Ends Testing of Experimental Alzheimer's Drug

Date : 12/03/2012 @ 4:22PM
Source : Dow Jones News
Stock : Johnson & Johnson (JNJ)
Quote : 131.39  -0.36 (-0.27%) @ 4:01PM
Johnson & Johnson share price Chart

Bristol-Myers Ends Testing of Experimental Alzheimer's Drug

Bristol Myers Sqibb (NYSE:BMY)
Historical Stock Chart

5 Years : From Sep 2012 to Sep 2017

Click Here for more Bristol Myers Sqibb Charts.
    By Peter Loftus 

Bristol-Myers Squibb Co. (BMY) has terminated its development of an experimental Alzheimer's disease treatment, saying the efficacy results of clinical testing so far didn't justify further development.

The company recently assessed results from a midstage, or phase 2, clinical study of avagacestat in mild-to-moderate Alzheimer's patients, as well as an ongoing phase 2 study in predementia patients.

"The evaluation did not establish a profile that supported advancement to Phase 3 development," the New York-based drug maker said in a statement posted on its website Friday.

Bristol said dosing in the ongoing phase 2 study will be discontinued as soon as it's feasible.

The company conducted an interim analysis in November of the study in predementia patients. "No new safety issues emerged in this interim analysis; however, the efficacy observed did not justify further development when evaluated in the context of all avagacestat data," the company said.

Bristol-Myers had previously expressed hope that testing avagacestat in patients with few or no symptoms of Alzheimer's would yield promising results. Standard practice has been to test experimental treatments in mild-to-moderate Alzheimer's.

Avagacestat is the latest experimental Alzheimer's drug to fail in clinical testing. Earlier this year, Johnson & Johnson (JNJ) and Pfizer Inc. (PFE) ended development of an intravenous formulation of bapineuzumab after it failed to show significant benefit in testing.

Current treatments don't stop the progression of the underlying disease, which impairs memory and cognitive skills primarily in the elderly. About 5 million Americans are estimated to have Alzheimer's.

Drug makers are continuing to study potential new treatments, however. On Monday, Merck & Co. (MRK) announced it is starting a new clinical trial of experimental Alzheimer's drug MK-8931.

And Eli Lilly & Co. (LLY) hasn't given up on its experimental Alzheimer's drug solanezumab after reporting mixed efficacy results from clinical testing.

Write to Peter Loftus at

Subscribe to WSJ:

Latest JNJ Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V:us D:20170923 16:12:51